External Beam Partial Breast Irradiation Most Cost-effective Treatment

June 4, 2009

External beam partial breast irradiation (EB-PBI) is the most cost-effective method for treating postmenopausal women with early-stage breast cancer based on utilities, recurrence risks and costs when compared to whole breast radiotherapy (WBRT) and brachytherapy partial breast irradiation (brachy-PBI), according to a study in the June 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).
Read the rest of this entry »

Advertisements

In Trastuzumab-Resistant Metastatic Breast Cancer, Small Molecule Inhibitor Shows Promise

May 30, 2009

Fox Chase Cancer Center researchers report that a combination of trastuzumab and neratinib (HKI-272) a novel small molecule inhibitor of the HER2 receptor (ErbB2) appears active in women with HER2-positive metastatic breast cancer who have progressed on previous trastuzumab based therapies. More than one-quarter of the women in a phase I/II trial had their tumors shrink on the combination therapy.

“I think this is very promising. Neratinib induces clinically meaningful responses,” says Ramona Swaby, M.D., a medical oncologist and attending physician at Fox Chase. Swaby will present the study results on Monday, June 1, at the annual meeting of the American Society of Clinical Oncology.
Read the rest of this entry »


Chemotherapy Chosen By More Older Women With Early Stage Breast Cancer

May 16, 2009

A new study examining treatment decision-making by older women with early stage breast cancer shows that 45 percent of women would choose to get chemotherapy after surgery — a figure higher than the national average of women getting the additional treatment.

“This was an unexpected finding,” says the study’s lead investigator, Jeanne Mandelblatt, MD, MPH, associate director for population sciences at GUMC’s Lombardi Comprehensive Cancer Center and professor of oncology and medicine at GUMC. “While these numbers are in contrast with the uniformly high use of chemotherapy in younger early-stage breast cancer patients, they suggest that older women are learning more about their disease and may be weighing the risks and benefits more thoroughly.”
Read the rest of this entry »


Gene Signature Predicts Good Outcome In Breast Cancer

May 15, 2009

Researchers have identified a genetic signature that can predict an improved clinical outcome in patients with breast cancer, and which could help in the development of new targeted therapies.

By analysing the expression of different genes induced by a specific mutation in a molecule called PIK3CA, a critical part of the pathway commonly deregulated in breast cancer, they found that these genes were correlated with an improved clinical outcome in over 1500 women with the disease.
Read the rest of this entry »


New Women’s Imaging Technique Allows For A More Accurate Diagnosis Of Breast Cancer

April 24, 2009

Breast elastography allows physicians to give a more accurate diagnosis of breast cancer, according to a study performed at Singapore General Hospital in Singapore. Breast elastography is a new technique which looks at the mechanical properties of tissues (relative stiffness) as opposed to conventional ultrasound which looks at the backscatter of transmitted ultrasound waves through tissues.

Ninety-nine women with 110 sonographically visible lesions were evaluated with ultrasound, elastography and combined ultrasound and elastography. 26 lesions were malignant and 84 were benign on histology. “All breast cancers (100%) in the study were diagnosed correctly by elastography alone compared to 88.5% by conventional ultrasound,” said Llewellyn Sim, MD, lead author of the study. “The use of breast elastography alone or combined with ultrasound provides a more accurate diagnosis of breast cancer,” said Dr. Sim.
Read the rest of this entry »


Large Study Documents How P53 Mutations Link To High-Grade Breast Cancer, Poor Outcomes

April 21, 2009

In what is believed to be the largest study of its kind in the US, researchers have found that almost 26 percent of women studied who have breast cancer have mutations in a gene important in controlling cell growth and death, and that patients with mutations in this gene – known as p53 – had poorer outcomes including a significantly increased risk of death from the cancer.

Researchers say their study, presented at the Annual Meeting of the American Association for Cancer Research (AACR), confirm the findings of other smaller studies, and is an important step forward in understanding risk factors that lead to development of breast cancer.
Read the rest of this entry »


Pueraria mirifica for breast enhancement

April 18, 2009

Question:

Hi! I am 28 years old with three children. I have been thin all my life and have zero breast tissue. I am considering breast augmentation with a highly reputable plastic surgeon but am worried with all the research I have been reading about silicone breast implants. I came across “pueraria mirifica” breast enhancement pills while surfing the web and was wondering if they are safe to take. I am healthy and am not on any medications. I would also like to know which is safer for my LONG TERM health. (I am not talking about risks of anesthesia, cost, recovery, etc). Your response is greatly appreciated.

Read the rest of this entry »